Show simple item record

dc.contributor.authorMukonzo, Jackson K.
dc.contributor.authorRöshammar, Daniel
dc.contributor.authorWaako, Paul
dc.contributor.authorAndersson, Maria
dc.contributor.authorFukasawa, Takashi
dc.contributor.authorMilani, Lili
dc.contributor.authorSvensson, Jan Olof
dc.contributor.authorOgwal-Okeng, Jasper
dc.contributor.authorGustafsson, Lars L.
dc.contributor.authorAklillu, Eleni
dc.date.accessioned2021-12-12T11:40:17Z
dc.date.available2021-12-12T11:40:17Z
dc.date.issued2009
dc.identifier.citationMukonzo, JK (2009). Rö shammar D, Waako P, Andersson M, Fukasawa T, Milani L, et al. A novel polymorphism in ABCB1 gene, CYP2B646 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. British journal of clinical pharmacology , 68 (5), 690-9.en_US
dc.identifier.other10.1111/j.1365-2125.2009.03516.x
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/339
dc.description.abstractEfavirenz, a potent antiretroviral agent, is the cornerstone of highly active antiretroviral therapy (HAART), particularly in human immunodeficiency virus (HIV) and tuberculosis co-infected patients being co-treated with rifampicin. Its essential role as an affordable HAART treatment in resource-poor countries is due to its relatively low cost, manageable pill burden and solid efficacy as well as safety documentationen_US
dc.language.isoenen_US
dc.publisherBritish journal of clinical pharmacologyen_US
dc.subjectABCB1en_US
dc.subjectCYP2B6en_US
dc.subjectCYP3A5en_US
dc.subjectEfavirenzen_US
dc.subjectPopulation pharmacokineticsen_US
dc.subjectUgandansen_US
dc.titleA novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandansen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record